{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:03:26Z","timestamp":1793678606071,"version":"4.5.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1136\/ard-2023-224489","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T20:00:52Z","timestamp":1702324852000},"page":"351-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct02749292","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-4549","authenticated-orcid":false,"given":"Reza","family":"Zonozi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank B","family":"Cortazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushya","family":"Jeyabalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9485-491X","authenticated-orcid":false,"given":"Gabriel","family":"Sauvage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravarut","family":"Nithagon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah R","family":"Huizenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian M","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sipilief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A","family":"Laliberte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene P","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William F","family":"Pendergraft,","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L","family":"Niles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224489_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.rdc.2018.06.001","article-title":"Renal involvement in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"44","author":"Zonozi","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard-2023-224489_bib2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.08821209","article-title":"Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"5","author":"Rhee","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1136\/ard-2023-224489_bib3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1136\/ard-2023-224489_bib4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224489_bib5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2021-220408","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response","volume":"80","author":"Bonelli","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224489_bib6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224489_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.41501","article-title":"Incidence, clinical features, and outcomes of late\u2010onset neutropenia from rituximab for autoimmune disease","volume":"73","author":"Zonozi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224489_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12905-021-01423-0","article-title":"Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders","volume":"21","author":"Yockey","year":"2021","journal-title":"BMC Womens Health"},{"key":"10.1136\/ard-2023-224489_bib9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.7326\/L20-1199","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2023-224489_bib10","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224489_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1523-1755.2003.00821.x","article-title":"Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis","volume":"63","author":"Han","year":"2003","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2023-224489_bib12","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten\u2010year experience at a single center","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis & Rheumatism"},{"key":"10.1136\/ard-2023-224489_bib13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2014a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224489_bib14","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/ndt\/gfaa066","article-title":"PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab","volume":"36","author":"van Dam","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2023-224489_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224489_bib16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10157-013-0869-6","article-title":"Overview of the 2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"17","author":"Jennette","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1136\/ard-2023-224489_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0140-6736(90)92205-V","article-title":"Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre","volume":"336","author":"Cohentervaert","year":"1990","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224489_bib18","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","article-title":"Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study","volume":"43","author":"Boomsma","year":"2000","journal-title":"Arthritis & Rheumatism"},{"key":"10.1136\/ard-2023-224489_bib19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease\u2010specific activity index for Wegener's granulomatosis: modification of the Birmingham vasculitis activity score","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis & Rheumatism"},{"key":"10.1136\/ard-2023-224489_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224489_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/art.42556","article-title":"Association between plasma rituximab concentration and the risk of major relapse in antineutrophil cytoplasmic antibody-associated vasculitides during rituximab maintenance therapy","author":"Khoudour","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224489_bib22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224489_bib23","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224489_bib24","first-page":"159","article-title":"COVID-19 recovery without B cells or antibodies in patients receiving rituximab for autoimmune disease","volume":"1","author":"Zonozi","year":"2021","journal-title":"Iran J Kidney Dis"},{"key":"10.1136\/ard-2023-224489_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.autrev.2017.05.008","article-title":"Interstital lung disease in ANCA vasculitis","volume":"16","author":"Alba","year":"2017","journal-title":"Autoimmun Rev"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:45:35Z","timestamp":1737348335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724003637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0003496724003637"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224489","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}